FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 46 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR Dormant Tumor Cells Can Be Sensitized to Chemotherapy February 20, 2019 ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps... January 31, 2022 Alzheimer’s-Linked Protein May Help Melanoma Spread to Brain April 1, 2022 Airbrushed Magazines Hurt the Body Image of Young Women — Here’s... May 19, 2021 Load more HOT NEWS Speaking a thousand words – how a cancer image collection is... ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC
